StockpollyBeta
Get App
Popularity #3,302
PROK · NASDAQ · Biotechnology

ProKidney (PROK)

Develops rilparencel for advanced chronic kidney disease and type 2 diabetes.

$1.76
vs last close−0.08 (−4.10%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000110
Gross profit000000000−1−10
472440434952424039444449
Research & development322327293140272627343436
1421314181214141261112
General & administrative1421314181214141261112
Other expenses0000000004−10
Operating income−47−24−40−43−49−52−41−40−39−45−45−48
655565443322
Interest income655565443322
Interest expense000000000000
Other non-operating income−6−5−5−5−6−5−4−4−3−3−2−2
Income before tax−41−19−35−39−43−47−37−36−35−42−43−46
Income tax expense1300−22111−2−200
Net income from continuing operations−42−22−35−38−41−48−38−37−36−41−23−46
Net income−11−6−9−13−18−21−17−17−16−19−23−28
EPS, basic−$0.18−$0.10−$0.16−$0.16−$0.14−$0.17−$0.13−$0.13−$0.12−$0.14−$0.16−$0.15
EPS, diluted−$0.18−$0.10−$0.16−$0.16−$0.14−$0.17−$0.13−$0.13−$0.12−$0.14−$0.16−$0.15
Weighted average shares, basic62606176126128129131135140142187
Weighted average shares, diluted62606176126128129131135140142187
EBITDA−40−18−34−37−42−45−36−35−34−41−41−45
Depreciation & amortization111112212111
EBIT−41−19−35−39−43−47−37−36−35−42−43−46